Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.

Sullivan NL, Reuter-Monslow MA, Sei J, Durr E, Davis CW, Chang C, McCausland M, Wieland A, Krah D, Rouphael N, Mehta AK, Mulligan MJ, Pulendran B, Ahmed R, Vora KA.

J Virol. 2018 Jun 29;92(14). pii: e00269-18. doi: 10.1128/JVI.00269-18. Print 2018 Jul 15.

PMID:
29743372
2.

Performance of the Asthma Impact on Quality of Life Scale (A-IQOLS) in diverse asthma research populations and demographic subgroups.

Wilson SR, Wise RA, Castro M, Mulligan MJ, Ayala E, Chausow A, Huang Q, Gummidipundi S.

J Allergy Clin Immunol. 2018 May 4. pii: S0091-6749(18)30634-1. doi: 10.1016/j.jaci.2018.02.056. [Epub ahead of print]

PMID:
29729942
3.

A High Throughput Whole Blood Assay for Analysis of Multiple Antigen-Specific T Cell Responses in Human Mycobacterium tuberculosis Infection.

Whatney WE, Gandhi NR, Lindestam Arlehamn CS, Nizam A, Wu H, Quezada MJ, Campbell A, Allana S, Kabongo MM, Khayumbi J, Muchiri B, Ongalo J, Tonui J, Sasser LE, Fergus TJ, Ouma GS, Ouma SG, Beck AA, Mulligan MJ, Oladele A, Kaushal D, Cain KP, Waller L, Blumberg HM, Altman JD, Ernst JD, Rengarajan J, Day CL; TBRU-ASTRa Study Group.

J Immunol. 2018 Apr 15;200(8):3008-3019. doi: 10.4049/jimmunol.1701737. Epub 2018 Mar 14.

PMID:
29540577
4.

Caregiver and adolescent factors associated with delayed completion of the three-dose human papillomavirus vaccination series.

Widdice LE, Hoagland R, Callahan ST, Kahn JA, Harrison CJ, Pahud BA, Frey SE, Berry AA, Kotloff KL, Edwards KM, Mulligan MJ, Sudman J, Nakamura A, Bernstein DI.

Vaccine. 2018 Mar 7;36(11):1491-1499. doi: 10.1016/j.vaccine.2017.12.060. Epub 2018 Feb 7.

PMID:
29428177
5.

Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine.

Levin MJ, Cai GY, Lee KS, Rouphael NG, Mehta AK, Canniff J, Mulligan MJ, Weinberg A.

J Infect Dis. 2018 Mar 13;217(7):1055-1059. doi: 10.1093/infdis/jix653.

PMID:
29409017
6.

Measurement of Human Immunodeficiency Virus p24 Antigen in Human Cerebrospinal Fluid With Digital Enzyme-Linked Immunosorbent Assay and Association With Decreased Neuropsychological Performance.

Anderson AM, Tyor WR, Mulligan MJ, Waldrop-Valverde D, Lennox JL, Letendre SL.

Clin Infect Dis. 2018 Jun 18;67(1):137-140. doi: 10.1093/cid/ciy056.

PMID:
29385540
7.

Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals.

Widdice LE, Unger ER, Panicker G, Hoagland R, Callahan ST, Jackson LA, Berry AA, Kotloff K, Frey SE, Harrison CJ, Pahud BA, Edwards KM, Mulligan MJ, Sudman J, Bernstein DI.

Vaccine. 2018 Feb 1;36(6):881-889. doi: 10.1016/j.vaccine.2017.12.042. Epub 2018 Jan 3.

PMID:
29306506
8.

Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

Jackson LA, El Sahly HM, George S, Winokur P, Edwards K, Brady RC, Rouphael N, Keitel WA, Mulligan MJ, Burton RL, Nakamura A, Ferreria J, Nahm MH.

Vaccine. 2018 Jan 29;36(5):606-614. doi: 10.1016/j.vaccine.2017.12.061. Epub 2017 Dec 24.

PMID:
29279281
9.

Origin and differentiation of human memory CD8 T cells after vaccination.

Akondy RS, Fitch M, Edupuganti S, Yang S, Kissick HT, Li KW, Youngblood BA, Abdelsamed HA, McGuire DJ, Cohen KW, Alexe G, Nagar S, McCausland MM, Gupta S, Tata P, Haining WN, McElrath MJ, Zhang D, Hu B, Greenleaf WJ, Goronzy JJ, Mulligan MJ, Hellerstein M, Ahmed R.

Nature. 2017 Dec 21;552(7685):362-367. doi: 10.1038/nature24633. Epub 2017 Dec 13.

10.

Microneedle patch for immunization of immunocompromised hosts.

Rouphael NG, Mulligan MJ.

Oncotarget. 2017 Oct 25;8(55):93311-93312. doi: 10.18632/oncotarget.22072. eCollection 2017 Nov 7. No abstract available.

11.

Theory-Based Analysis of Interest in an HIV Vaccine for Reasons Indicative of Risk Compensation Among African American Women.

Painter JE, Temple BS, Woods LA, Cwiak C, Haddad LB, Mulligan MJ, DiClemente RJ.

Health Educ Behav. 2018 Jun;45(3):444-453. doi: 10.1177/1090198117736860. Epub 2017 Oct 26.

PMID:
29073834
12.

Survival of Lung Transplant Candidates With COPD: BODE Score Reconsidered.

Reed RM, Cabral HJ, Dransfield MT, Eberlein M, Merlo CA, Mulligan MJ, Netzer G, Sanchez PG, Scharf SM, Sin DD, Celli BR.

Chest. 2018 Mar;153(3):697-701. doi: 10.1016/j.chest.2017.10.008. Epub 2017 Oct 17.

PMID:
29054348
13.

Innate, T-, and B-Cell Responses in Acute Human Zika Patients.

Lai L, Rouphael N, Xu Y, Natrajan MS, Beck A, Hart M, Feldhammer M, Feldpausch A, Hill C, Wu H, Fairley JK, Lankford-Turner P, Kasher N, Rago P, Hu YJ, Edupuganti S, Patel SM, Murray KO, Mulligan MJ; Emory Zika Patient Study Team .

Clin Infect Dis. 2018 Jan 6;66(1):1-10. doi: 10.1093/cid/cix732.

14.

Biphasic Zika Illness With Rash and Joint Pain.

Edupuganti S, Natrajan MS, Rouphael N, Lai L, Xu Y, Feldhammer M, Hill C, Patel SM, Johnson SJ, Bower M, Gorchakov R, Berry R, Murray KO, Mulligan MJ.

Open Forum Infect Dis. 2017 Jun 22;4(3):ofx133. doi: 10.1093/ofid/ofx133. eCollection 2017 Summer.

15.

Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.

Mulligan MJ, Stapleton JT, Keitel WA, Frey SE, Chen WH, Rouphael N, Edupuganti S, Beck A, Winokur PL, El Sahly HM, Patel SM, Atmar RL, Graham I, Anderson E, El-Kamary SS, Pasetti MF, Sztein MB, Hill H, Goll JB; DMID 08-0006 Tularemia Vaccine Study Group.

Vaccine. 2017 Aug 24;35(36):4730-4737. doi: 10.1016/j.vaccine.2017.07.024. Epub 2017 Jul 24.

16.

Pericarditis Associated With Acute Zika Virus Infection in a Returning Traveler.

Waggoner JJ, Rouphael N, Xu Y, Natrajan M, Lai L, Patel SM, Levit RD, Edupuganti S, Mulligan MJ.

Open Forum Infect Dis. 2017 May 18;4(2):ofx103. doi: 10.1093/ofid/ofx103. eCollection 2017 Spring.

17.

The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.

Rouphael NG, Paine M, Mosley R, Henry S, McAllister DV, Kalluri H, Pewin W, Frew PM, Yu T, Thornburg NJ, Kabbani S, Lai L, Vassilieva EV, Skountzou I, Compans RW, Mulligan MJ, Prausnitz MR; TIV-MNP 2015 Study Group.

Lancet. 2017 Aug 12;390(10095):649-658. doi: 10.1016/S0140-6736(17)30575-5. Epub 2017 Jun 27.

18.

A new measure to assess asthma's effect on quality of life from the patient's perspective.

Wilson SR, Mulligan MJ, Ayala E, Chausow A, Huang Q, Knowles SB, Gummidipundi S, Castro M, Wise RA.

J Allergy Clin Immunol. 2018 Mar;141(3):1085-1095. doi: 10.1016/j.jaci.2017.02.047. Epub 2017 Jun 1.

PMID:
28579376
19.

Exploring evidence for behavioral risk compensation among participants in an HIV vaccine clinical trial.

Painter JE, DiClemente RJ, Jimenez L, Stuart T, Sales JM, Mulligan MJ.

Vaccine. 2017 Jun 16;35(28):3558-3563. doi: 10.1016/j.vaccine.2017.05.024. Epub 2017 May 19.

PMID:
28533053
20.

Metabolic Phenotypes of Response to Vaccination in Humans.

Li S, Sullivan NL, Rouphael N, Yu T, Banton S, Maddur MS, McCausland M, Chiu C, Canniff J, Dubey S, Liu K, Tran V, Hagan T, Duraisingham S, Wieland A, Mehta AK, Whitaker JA, Subramaniam S, Jones DP, Sette A, Vora K, Weinberg A, Mulligan MJ, Nakaya HI, Levin M, Ahmed R, Pulendran B.

Cell. 2017 May 18;169(5):862-877.e17. doi: 10.1016/j.cell.2017.04.026. Epub 2017 May 11.

21.

Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.

Jackson LA, Frey SE, El Sahly HM, Mulligan MJ, Winokur PL, Kotloff KL, Campbell JD, Atmar RL, Graham I, Anderson EJ, Anderson EL, Patel SM, Fields C, Keitel W, Rouphael N, Hill H, Goll JB.

Vaccine. 2017 Mar 23;35(13):1675-1682. doi: 10.1016/j.vaccine.2017.02.032. Epub 2017 Feb 27.

PMID:
28256358
22.

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.

Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, Mulligan MJ, Koblin B, Buchbinder SP, Keefer MC, Adams E, Anude C, Corey L, Sobieszczyk M, Hammer SM, Gilbert PB, McElrath MJ.

J Infect Dis. 2017 May 1;215(9):1376-1385. doi: 10.1093/infdis/jix086.

23.

The rectal mucosa and condomless receptive anal intercourse in HIV-negative MSM: implications for HIV transmission and prevention.

Kelley CF, Kraft CS, de Man TJ, Duphare C, Lee HW, Yang J, Easley KA, Tharp GK, Mulligan MJ, Sullivan PS, Bosinger SE, Amara RR.

Mucosal Immunol. 2017 Jul;10(4):996-1007. doi: 10.1038/mi.2016.97. Epub 2016 Nov 16.

24.

A Novel Large Animal Model of Acute Respiratory Distress Syndrome Induced by Mitochondrial Products.

Sanchez PG, Pasrija C, Mulligan MJ, Wadhwa M, Pratt DL, Li T, Gammie JS, Kon ZN, Pham SM, Griffith BP.

Ann Surg. 2017 Dec;266(6):1091-1096. doi: 10.1097/SLA.0000000000002011.

PMID:
27735823
25.

Prolonged Detection of Zika Virus in Vaginal Secretions and Whole Blood.

Murray KO, Gorchakov R, Carlson AR, Berry R, Lai L, Natrajan M, Garcia MN, Correa A, Patel SM, Aagaard K, Mulligan MJ.

Emerg Infect Dis. 2017 Jan;23(1):99-101. doi: 10.3201/eid2301.161394. Epub 2017 Jan 15.

26.

Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype.

Dowd KA, DeMaso CR, Pelc RS, Speer SD, Smith ARY, Goo L, Platt DJ, Mascola JR, Graham BS, Mulligan MJ, Diamond MS, Ledgerwood JE, Pierson TC.

Cell Rep. 2016 Aug 9;16(6):1485-1491. doi: 10.1016/j.celrep.2016.07.049. Epub 2016 Jul 29.

27.

Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus.

Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S, Pattanapanyasat K, Chokephaibulkit K, Mulligan MJ, Wilson PC, Ahmed R, Suthar MS, Wrammert J.

Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7852-7. doi: 10.1073/pnas.1607931113. Epub 2016 Jun 27.

28.

Editorial overview: Preventive and therapeutic vaccines.

Robinson HL, Mulligan MJ.

Curr Opin Virol. 2016 Apr;17:viii-x. doi: 10.1016/j.coviro.2016.05.006. No abstract available.

PMID:
27283522
29.

The use of extended criteria donors decreases one-year survival in high-risk lung recipients: A review of the United Network of Organ Sharing Database.

Mulligan MJ, Sanchez PG, Evans CF, Wang Y, Kon ZN, Rajagopal K, Iacono AT, Gammie JS, Griffith BP, Pham SM.

J Thorac Cardiovasc Surg. 2016 Sep;152(3):891-898.e2. doi: 10.1016/j.jtcvs.2016.03.096. Epub 2016 Apr 28.

30.

Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus.

Wong KK, Davey RT Jr, Hewlett AL, Kraft CS, Mehta AK, Mulligan MJ, Beck A, Dorman W, Kratochvil CJ, Lai L, Palmore TN, Rogers S, Smith PW, Suffredini AF, Wolcott M, Ströher U, Uyeki TM.

Clin Infect Dis. 2016 Aug 1;63(3):376-9. doi: 10.1093/cid/ciw256. Epub 2016 Apr 26.

31.

Differences in expression of gut-homing receptors on CD4+ T cells in black and white HIV-negative men who have sex with men.

Kelley CF, Lai L, Ibegbu C, Rosenberg ES, Kaur S, Patel K, Mulligan MJ, Marconi VC, Sullivan PS, Amara RR.

AIDS. 2016 May 15;30(8):1305-8. doi: 10.1097/QAD.0000000000001062.

32.

Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures.

Nakaya HI, Hagan T, Duraisingham SS, Lee EK, Kwissa M, Rouphael N, Frasca D, Gersten M, Mehta AK, Gaujoux R, Li GM, Gupta S, Ahmed R, Mulligan MJ, Shen-Orr S, Blomberg BB, Subramaniam S, Pulendran B.

Immunity. 2015 Dec 15;43(6):1186-98. doi: 10.1016/j.immuni.2015.11.012.

33.

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X; HVTN 083 Study Group and the NIAID HVTN.

J Infect Dis. 2016 Feb 15;213(4):541-50. doi: 10.1093/infdis/jiv496. Epub 2015 Oct 15.

34.

Era of global Ebola: risk of exposure in health-care workers.

Mulligan MJ, Siebert PN.

Lancet Infect Dis. 2015 Nov;15(11):1248-9. doi: 10.1016/S1473-3099(15)00291-1. Epub 2015 Aug 25. No abstract available.

PMID:
26321190
35.

Explaining racial disparities in HIV incidence in black and white men who have sex with men in Atlanta, GA: a prospective observational cohort study.

Sullivan PS, Rosenberg ES, Sanchez TH, Kelley CF, Luisi N, Cooper HL, Diclemente RJ, Wingood GM, Frew PM, Salazar LF, Del Rio C, Mulligan MJ, Peterson JL.

Ann Epidemiol. 2015 Jun;25(6):445-54. doi: 10.1016/j.annepidem.2015.03.006. Epub 2015 Mar 24.

36.

The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States.

Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, Varkey JB, Mehta AK, Lyon GM 3rd, Friedman-Moraco RJ, Marconi VC, Hill CE, Sullivan JN, Johnson DW, Lisco SJ, Mulligan MJ, Uyeki TM, McElroy AK, Sealy T, Campbell S, Spiropoulou C, Ströher U, Crozier I, Sacra R, Connor MJ Jr, Sueblinvong V, Franch HA, Smith PW, Ribner BS; Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit.

Clin Infect Dis. 2015 Aug 15;61(4):496-502. doi: 10.1093/cid/civ334. Epub 2015 Apr 22.

37.

Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.

Lai L, Davey R, Beck A, Xu Y, Suffredini AF, Palmore T, Kabbani S, Rogers S, Kobinger G, Alimonti J, Link CJ Jr, Rubinson L, Ströher U, Wolcott M, Dorman W, Uyeki TM, Feldmann H, Lane HC, Mulligan MJ.

JAMA. 2015 Mar 24-31;313(12):1249-55. doi: 10.1001/jama.2015.1995.

38.

Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.

Mulligan MJ, Bernstein DI, Frey S, Winokur P, Rouphael N, Dickey M, Edupuganti S, Spearman P, Anderson E, Graham I, Noah DL, Mangal B, Kim S, Hill H, Whitaker J, Emery W, Beck A, Stephens K, Hartwell B, Ogilvie M, Rimann N, Osinski E, Destefano E, Gajadhar T, Strudwick A, Pierce K, Lai L, Yue L, Wang D, Ying C, Cline A, Foltz T, Wagner N, Dull G, Pacatte T, Taggart B, Johnson V, Haller L, Looney C, Li S, May M, Myers B, May R, Parker L, Cochran N, Bowen D, Bell M, Scoggins J, Burns A, Stablein C, Wolff M, Jolles B, Leung B, Lambert L, Shorer S, Buchanan W, Murray S, Chang S, Gorman R.

Open Forum Infect Dis. 2014 Nov 18;1(3):ofu102. doi: 10.1093/ofid/ofu102. eCollection 2014 Dec.

39.

Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination.

Akondy RS, Johnson PL, Nakaya HI, Edupuganti S, Mulligan MJ, Lawson B, Miller JD, Pulendran B, Antia R, Ahmed R.

Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):3050-5. doi: 10.1073/pnas.1500475112. Epub 2015 Feb 23.

40.

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old.

Keitel WA, Jackson LA, Edupuganti S, Winokur PL, Mulligan MJ, Thornburg NJ, Patel SM, Rouphael NG, Lai L, Bangaru S, McNeal MM, Bellamy AR, Hill HR; VTEU H3N2v Vaccine Study Work Group.

J Infect Dis. 2015 Aug 15;212(4):552-61. doi: 10.1093/infdis/jiv056. Epub 2015 Feb 3.

41.

Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.

Frey SE, Bernstein DI, Brady RC, Keitel WA, El Sahly H, Rouphael NG, Mulligan MJ, Atmar RL, Edupuganti S, Patel SM, Dickey M, Graham I, Anderson EL, Noah DL, Hill H, Wolff M, Belshe RB.

Vaccine. 2015 Jan 1;33(1):163-73. doi: 10.1016/j.vaccine.2014.10.083. Epub 2014 Nov 11.

42.

Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.

Belshe RB, Frey SE, Graham IL, Anderson EL, Jackson LA, Spearman P, Edupuganti S, Mulligan MJ, Rouphael N, Winokur P, Dolor RJ, Woods CW, Walter EB, Chen WH, Turley C, Edwards KM, Creech CB, Hill H, Bellamy AR; National Institute of Allergy and Infectious Diseases–Funded Vaccine and Treatment Evaluation Units.

JAMA. 2014 Oct 8;312(14):1420-8. doi: 10.1001/jama.2014.12609.

PMID:
25291578
43.

Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.

Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, Dickey M, Stapleton JT, Edupuganti S, Spearman P, Ince D, Noah DL, Hill H, Bellamy AR; DMID 13-0032 H7N9 Vaccine Study Group.

JAMA. 2014 Oct 8;312(14):1409-19. doi: 10.1001/jama.2014.12854.

PMID:
25291577
44.

Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.

Ellebedy AH, Krammer F, Li GM, Miller MS, Chiu C, Wrammert J, Chang CY, Davis CW, McCausland M, Elbein R, Edupuganti S, Spearman P, Andrews SF, Wilson PC, García-Sastre A, Mulligan MJ, Mehta AK, Palese P, Ahmed R.

Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13133-8. doi: 10.1073/pnas.1414070111. Epub 2014 Aug 25.

45.

A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation.

Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan MJ, Patterson GA, Singer LG, Snell GI, Verleden GM, Zamora MR, Glanville AR.

J Heart Lung Transplant. 2015 Jan;34(1):1-15. doi: 10.1016/j.healun.2014.06.014. Epub 2014 Jun 26. Review.

PMID:
25085497
46.

Social discrimination and resiliency are not associated with differences in prevalent HIV infection in black and white men who have sex with men.

Peterson JL, Bakeman R, Sullivan P, Millett GA, Rosenberg E, Salazar L, DiClemente RJ, Cooper H, Kelley CF, Mulligan MJ, Frew P, del Rio C.

J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):538-43. doi: 10.1097/QAI.0000000000000203.

47.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, DeRosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder SP, Hammer SM, Koblin BA, Pensiero M, Butler C, Moss B, Robinson HL; HVTN 205 Study Group; National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network.

J Infect Dis. 2014 Jul 1;210(1):99-110. doi: 10.1093/infdis/jiu003. Epub 2014 Jan 7.

48.

Molecular signatures of antibody responses derived from a systems biology study of five human vaccines.

Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, Schmidt DS, Johnson SE, Milton A, Rajam G, Kasturi S, Carlone GM, Quinn C, Chaussabel D, Palucka AK, Mulligan MJ, Ahmed R, Stephens DS, Nakaya HI, Pulendran B.

Nat Immunol. 2014 Feb;15(2):195-204. doi: 10.1038/ni.2789. Epub 2013 Dec 15.

49.

In response.

Edupuganti S, Mulligan MJ, Eidex RB, Cetron M, Marfin AA.

Am J Trop Med Hyg. 2013 Dec;89(6):1226-7. doi: 10.4269/ajtmh.13-0443b. No abstract available.

50.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB; HVTN 505 Study Team.

N Engl J Med. 2013 Nov 28;369(22):2083-92. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7.

Supplemental Content

Loading ...
Support Center